Literature DB >> 16905691

Tacrolimus--finally!

K R Herrlinger1, K Fellermann, E F Stange.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905691      PMCID: PMC1860029          DOI: 10.1136/gut.2006.093302

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  24 in total

1.  Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.

Authors:  K Fellermann; M Steffen; J Stein; A Raedler; J Hämling; D Ludwig; K Loeschke; E F Stange
Journal:  Aliment Pharmacol Ther       Date:  2000-02       Impact factor: 8.171

2.  Response of refractory colitis to intravenous or oral tacrolimus (FK506).

Authors:  Klaus Fellermann; Zita Tanko; Klaus R Herrlinger; Thomas Witthoeft; Nils Homann; Andreas Bruening; Diether Ludwig; Eduard F Stange
Journal:  Inflamm Bowel Dis       Date:  2002-09       Impact factor: 5.325

3.  Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.

Authors:  G D'Haens; L Lemmens; K Geboes; L Vandeputte; F Van Acker; L Mortelmans; M Peeters; S Vermeire; F Penninckx; F Nevens; M Hiele; P Rutgeerts
Journal:  Gastroenterology       Date:  2001-05       Impact factor: 22.682

4.  Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

Authors:  T Orth; M Peters; J F Schlaak; F Krummenauer; R Wanitschke; W J Mayet; P R Galle; M F Neurath
Journal:  Am J Gastroenterol       Date:  2000-05       Impact factor: 10.864

5.  Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease.

Authors:  A Stallmach; B M Wittig; C Moser; J Fischinger; R Duchmann; M Zeitz
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

6.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

7.  Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy.

Authors:  Devang N Prajapati; Joshua F Knox; Jeanne Emmons; Kia Saeian; Mary E Csuka; David G Binion
Journal:  J Clin Gastroenterol       Date:  2003-08       Impact factor: 3.062

8.  A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis.

Authors:  H Ogata; T Matsui; M Nakamura; M Iida; M Takazoe; Y Suzuki; T Hibi
Journal:  Gut       Date:  2006-02-16       Impact factor: 23.059

9.  Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease.

Authors:  D C Baumgart; B Wiedenmann; A U Dignass
Journal:  Aliment Pharmacol Ther       Date:  2003-05-15       Impact factor: 8.171

10.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.